Biofrontera Inc. Q4 2025 Earnings Call Summary

Financial Performance - Achieved record annual revenue of $41.7 million, driven by a 10% increase in Ameluz unit volumes and refined commercial targeting [5] - Improved gross margin profile significantly by replacing a 25-35% transfer pricing model with a 12-15% royalty-based earn-out structure [5] - Expects full-year 2026 gross profit margins to stabilize between 80% and 85% as the new cost structure applies to all sales volumes [5][7] Strategic Initiatives - Transformed the corporate structure by acquiring all U.S. rights, patents, and manufacturing contracts for Ameluz and RhodoLED from the former parent company [5] - Optimized sales operations by implementing a data-driven targeting approach and an inside sales pilot to capture previously underserved smaller accounts [5] - Divested the Xepi antibiotic cream license for $3 million in initial proceeds, with potential milestones up to $7 million to focus on core PDT assets [5] Clinical Development - Anticipates a PDUFA target action date of September 28, 2026, for the potential approval of Ameluz in treating superficial basal cell carcinoma [5] - Plans to file a supplemental NDA in 2026 to expand the Ameluz label for actinic keratosis on the extremities, neck, and trunk following positive Phase III results [5] - Intends to discuss the design of a Phase III program for moderate to severe acne vulgaris with the FDA in 2026 based on successful Phase II data [5] Operational Changes - Transitioned to full regulatory control in the U.S. following the formal FDA transfer of the NDA and IND in December 2025 [6] - Reduced customer churn to the lowest level since 2021 while successfully opening over 150 new accounts during the fiscal year [5] - Noted that legal expenses increased by $6.0 million in 2025 primarily due to ongoing patent litigation and defense costs [5]